Abstract
A novel approach is described to simulate effect site pharmacodynamics of anticancer drugs. This approach is based on (i) the in vivo measurement of unbound, interstitial drug pharmacokinetics (PK) in solid tumor lesions in patients and (ii) a subsequent pharmacodynamic (PD) simulation of the time versus drug concentration profile in an in vitro setting. For this purpose, breast cancer cells (MCF-7) were exposed in vitro to the time versus interstitial tumor concentration profiles of 5-fluorouracil (5-FU) and methotrexate (MTX) from primary breast cancer lesions in patients. This led to a maximal reduction in the viable cell count of 69 on day 4, and of 71 on day 7 for 5-FU and MTX, respectively. This effect was dependent on the initial cell count and was characterized by a high interindividual variability. For 5-FU there was a significant correlation between the maximum antitumor effect and the intratumoral AUC (r = 0.82, p = 0.0005), whereas no correlation could be shown for MTX (r = 0.05, p = 0.88). We conclude, that the in-vivo-PK / in-vitro-PD model presented in this study may provide a rational approach for describing and predicting pharmacodynamics of cytotoxic drugs at the target site. Data derived from this approach support the concept that tumor penetration of 5-FU may be a response-limiting event, while the response to MTX may be determined by events beyond interstitial fluid kinetics.
Similar content being viewed by others
References
vonHoff DD, Weisenthal L: In vitro methods to predict patient response to chemotherapy. Adv Pharmacol Chemother 7: 133–156, 1980
Huschtscha LI, Bartier WA, Ross CE, Tattersall MH: Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 73: 54–60, 1996
Levasseur LM, Slocum HK, Rustum YM, Greco WR: Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58: 5749–5761, 1998
Twentyman PR: Predictive chemosensitivity testing. J Cancer 51: 295–299, 1985
Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039–3051, 1987
Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst, 81: 570–576, 1989
Bateman AE, Peckham MJ, Steel GG: Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour. Br J Cancer 40: 81–88, 1979
Jain RK: Delivery of molecular medicine to solid tumors. Science 271: 1079–1080, 1996
Jain RK: The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4: 655–657, 1998
Müller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG, Blöchl-Daum B: 5-Fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res 57: 2598–2601, 1997
Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR: Association of intratumor pharmacokinetics of fluorouracil with clinical response. Lancet, 343: 1184–1187, 1994
Front D, Israel O, Iosilevsky G, Even-Sapir E, Frenkel A, Peleg H, Steiner M, Kuten A, Kolodny G: Human lung tumors: SPECT Quantitation of differences in Co-57 Bleomycin uptake. Radiology 165: 129–133, 1987.
Pujol JL, Cupissol D, Gestin-Boyer C, Bres J, Serrou B, Michel FB: Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small cell lung cancer patients. Cancer Chemother Pharmacol 27: 72–75, 1990
Müller M, Brunner M, Schmid R, Mader RM, Bockenheimer J, Steger GG, Steiner B, Eichler HG, Blöchl-Daum B: Interstitial methotrexate kinetics in primary breast cancer lesions. Cancer Res 58: 2982–2985, 1998.
Evans WE, Relling, MV: Clinical pharmacokineticspharmacodynamics of anticancer drugs. Clin Pharmacokinet 16: 327–336, 1989
Dalla Costa T, Nolting A, Rand K, Derendorf H. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 35: 426–433, 1997
Mader RM, Brunner M, Rizovski B, Mensik C, Steger GG, Eichler HG, Müller M: Analysis of microdialysates from cancer patients by capillary electrophoresis. Electrophoresis 19: 2981–2985, 1998
Mader RM, Steger GG, Müller M: Mechanisms of resistance to 5-FU. Gen Pharmacol 31: 661–666, 1998
Volm M: Multidrug resistance and its reversal. Anticancer Res 18: 2905–2917, 1998
St Croix B, Man S, Kerbel RS: Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett 131: 35–44, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller, M., Bockenheimer, J., Zellenberg, U. et al. Relationship between in vivo drug exposure of the tumor interstitium and inhibition of tumor cell growth in vitro: a study in breast cancer patients. Breast Cancer Res Treat 60, 211–217 (2000). https://doi.org/10.1023/A:1006497202341
Issue Date:
DOI: https://doi.org/10.1023/A:1006497202341